Investment Insider: The heady days aren't over for drugs groups

Genetics, stem cells and consistent dividends can offset the problems of expiring patents

The further away an operation is from head office, the less control central management has over the operation. It is something, perhaps, that GlaxoSmithKline might be more mindful of in future.

However, the travails of the UK's biggest drugs company in China might provide investors with an opportunity to take a closer look at the group. The shares have enjoyed a decent run over the last two years, climbing from around 1,250p in 2011 to a recent high of 1,777p in May this year, and it is encouraging that they have only wavered a little following allegations of bribery against senior executives in the company's China office.

The bottom line is that GlaxoSmithKline is a generous dividend payer, and there is little to suggest this will stop in the near future. That might explain why the shares remain in demand. Profits this year are expected to rise around 3 per cent to almost £7bn, while the full-year dividend payout is expected to rise 7 per cent to 77p, which would suggest a dividend yield of 4.5 per cent based on the current share price of 1,715p.

AstraZeneca is now experiencing the same patent-expiry pains endured by GlaxoSmithKline in the last few years. Revenues fell around 20 per cent last year as key drugs lost their protection against generic rivals. That said, AstraZeneca is expected to keep shareholders sweet by at least maintaining its dividend. A forecast payout of 191p would equate to a yield of 5.8 per cent.

Much has been said about the pharmaceutical industry being in decline, and in a sense that's true as drugmakers cannot continue to dine out on the chemical drugs of yesteryear. However, as healthcare keeps evolving, so biologics and pharmaceuticals will gradually merge and the drug companies of the future will be involved in areas such as genetics, stem-cell science and a host of other medical technologies.

Among these companies, neither ReNeuron nor Xenetic Biosciences is currently profitable, but that is not unusual for fledgling firms at the cutting edge of science. ReNeuron, which is worth around £23m, specialises in developing stem-cell therapies in areas where medical needs have not been met. It has a treatment for stroke patients in clinical development.

Xenetic, which is worth around £26m, specialises in novel ways of delivering drugs and vaccines. It reckons that its pipeline has multi-billion-pound market potential.

The pharmaceutical sector is peppered with companies that believe they can be the next GlaxoSmithKline or Amgen. The trouble is, the risk-reward ratio when investing in small biotechnology firms can be quite high, given that only one in 15 drugs that enter clinical trials go on to make money. Conversely, the rewards can be huge for the drug that does make it through.

Investors, though, probably have as much chance of spotting the next GlaxoSmithKline as fledgling biotechs have of actually becoming one. If you want to improve your chances, investing a little in each company is one way to spread your risk.

Alternatively, stick to the big drug groups. Many have collaborated with the small biotechs, so they should at least have their finger on the pulse.

David Kuo is director of

Independent Partners; request a free guide on NISAs from Hargreaves Lansdown

Arts and Entertainment
Rita Ora will replace Kylie Minogue as a judge on The Voice 2015
Life and Style
Life and Style
Alan Turing, who was convicted of gross indecency in 1952, was granted a royal pardon last year
Arts and Entertainment
Sheridan Smith as Cilla Black and Ed Stoppard as her manager Brian Epstein
tvCilla Episode 2 review: Grit under the glamour in part two of biopic series starring Sheridan Smith
Life and Style
Arts and Entertainment
Tennis player Andy Murray's mum Judy has been paired with Anton du Beke for Strictly Come Dancing. 'I'm absolutely delighted,' she said.
tvJudy Murray 'struggling' to let Anton Du Beke take control on Strictly
Life and Style
Vote with your wallet: the app can help shoppers feel more informed about items on sale
lifeNew app reveals political leanings of food companies
Arts and Entertainment
The cover of Dark Side of the Moon
musicCan 'The Endless River' carry on the tradition? See for yourself
New Zealand fly-half Aaron Cruden pictured in The Zookeeper's Son on a late-night drinking session
A new app has been launched that enables people to have a cuddle from a stranger
voicesMaybe the new app will make it more normal to reach out to strangers
Arts and Entertainment
Salmond told a Scottish television chat show in 2001that he would also sit in front of a mirror and say things like,
tvCelebrity Trekkies from Alex Salmond to Barack Obama
Finacial products from our partners
Property search
Latest stories from i100
Have you tried new the Independent Digital Edition apps?
Independent Dating

By clicking 'Search' you
are agreeing to our
Terms of Use.

ES Rentals

    iJobs Job Widget
    iJobs Money & Business

    IT Project manager - Web E-commerce

    £65000 Per Annum Benefits + bonus: Clearwater People Solutions Ltd: If you are...

    Trainee / Experienced Recruitment Consultants

    £20000 - £25000 per annum + OTE £40,000: SThree: SThree are a global FTSE 250 ...

    Trainee Recruitment Consultant - Soho

    £20000 - £25000 per annum + OTE £40000: SThree: As a Recruitment Consultant, y...

    Trainee Recruitment Consultants - Banking & Finance

    £20000 - £25000 per annum + OTE £40,000: SThree: SThree Group have been well e...

    Day In a Page

    Secret politics of the weekly shop

    The politics of the weekly shop

    New app reveals political leanings of food companies
    Beam me up, Scottie!

    Beam me up, Scottie!

    Celebrity Trekkies from Alex Salmond to Barack Obama
    Beware Wet Paint: The ICA's latest ambitious exhibition

    Beware Wet Paint

    The ICA's latest ambitious exhibition
    Pink Floyd have produced some of rock's greatest ever album covers

    Pink Floyd have produced some of rock's greatest ever album covers

    Can 'The Endless River' carry on the tradition?
    Sanctuary for the suicidal

    Sanctuary for the suicidal

    One mother's story of how London charity Maytree helped her son with his depression
    A roller-coaster tale from the 'voice of a generation'

    Not That Kind of Girl:

    A roller-coaster tale from 'voice of a generation' Lena Dunham
    London is not bedlam or a cradle of vice. In fact it, as much as anywhere, deserves independence

    London is not bedlam or a cradle of vice

    In fact it, as much as anywhere, deserves independence
    Vivienne Westwood 'didn’t want' relationship with Malcolm McLaren

    Vivienne Westwood 'didn’t want' relationship with McLaren

    Designer 'felt pressured' into going out with Sex Pistols manager
    Jourdan Dunn: Model mother

    Model mother

    Jordan Dunn became one of the best-paid models in the world
    Apple still coolest brand – despite U2 PR disaster

    Apple still the coolest brand

    Despite PR disaster of free U2 album
    Scottish referendum: The Yes vote was the love that dared speak its name, but it was not to be

    Despite the result, this is the end of the status quo

    Boyd Tonkin on the fall-out from the Scottish referendum
    Manolo Blahnik: The high priest of heels talks flats, Englishness, and why he loves Mary Beard

    Manolo Blahnik: Flats, Englishness, and Mary Beard

    The shoe designer who has been dubbed 'the patron saint of the stiletto'
    The Beatles biographer reveals exclusive original manuscripts of some of the best pop songs ever written

    Scrambled eggs and LSD

    Behind The Beatles' lyrics - thanks to Hunter Davis's original manuscript copies
    'Normcore' fashion: Blending in is the new standing out in latest catwalk non-trend

    'Normcore': Blending in is the new standing out

    Just when fashion was in grave danger of running out of trends, it only went and invented the non-trend. Rebecca Gonsalves investigates
    Dance’s new leading ladies fight back: How female vocalists are now writing their own hits

    New leading ladies of dance fight back

    How female vocalists are now writing their own hits